We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Sebia Showcases HbA1c Testing Solutions for Every Size Laboratory at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Sebia provides a solution for every size laboratory for HbA1c testing (Photo courtesy of Sebia)
Image: Sebia provides a solution for every size laboratory for HbA1c testing (Photo courtesy of Sebia)

Sebia (Lisses, France) is showcasing its wide portfolio of instruments and tests designed to address clinical needs and improve laboratory efficiency and safety at the 2022 AACC Clinical Lab Expo. From the lowest to the highest volumes, with standalone instruments to workcell configurations, Sebia will highlight various solutions for laboratories at the event.

At AACC 2022, Sebia is demonstrating the CAPILLARYS 3 TERA MC high throughput capillary electrophoresis system that allows the combination of one to three CAPILLARYS 3 TERA instruments to a Sebia loader, with a loading capacity of 528 samples in one row. This high volume workcell provides three hours autonomy on HbA1c, and hemoglobin testing, and more than two hours on proteins, processing up to 528 samples in one go. The system can be fed continuously with additional racks, and the reagent management system allows ad-hoc reagent addition at any time, without interruption. Sebia also highlighted its portfolio of tests from multiple myeloma to metabolic disorders, hemoglobinopathies and genetic diseases.

In addition, Sebia will showcase its fully automated, random access Alegria 2 ELISA platform with its comprehensive menu of antigen assays & panels utilizing a unique Monotest strip technology that allows serum, plasma, and fecal sample testing in the same run. Visitors to the company’s AACC 2022 booth can learn about Phoresis CORE, the unified software solution for labs utilizing Sebia instruments which offers traceable patient sampling from reagent to result, remote interpretation in real-time, from anywhere, and with comprehensive patient history for all of its assays. Visitors can also learn how labs can partner with the company for its Sebia Workflow Service to maximize automation, reduce errors, and improve workflow.
 

Related Links:
Sebia 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.